, Volume 184, Issue 1, pp 147–150 | Cite as

Prognostic Potential of the Panfungal Marker (1 → 3)-β-d-Glucan in Invasive Mycoses Patients

  • P. Pini
  • C. Venturelli
  • M. Girardis
  • F. Forghieri
  • E. BlasiEmail author
Short Communication


We analyze the prognostic potential of (1 → 3)-β-d-glucan (BG) levels in predicting clinical outcomes in patients with invasive fungal infections, on a population undergoing 253 episodes (177 with positive and 76 with negative outcome). Using linear regression analysis, we assessed the prognostic potential of kinetically evaluated BG levels and we found an overall sensitivity and specificity of 68 and 82%, respectively. Moreover, using an interpretative algorithm based on two distinct cutoff values, we were able to predict the outcome in 84% of the studied population with a diagnostic accuracy of 82%.


Beta glucan Panfungal marker Invasive fungal infections Prognostic evaluation 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All the procedures performed in the study, involving elaboration of data obtained from biological samples, were in accordance with the ethical standards of the local institutional research committee (regularly approved protocols Nos. 53/11 and 251/17) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.


  1. 1.
    Talento AF, Dunne K, Joyce EA, et al. A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit. J Crit Care. 2017;40:119–27. Scholar
  2. 2.
    Pini P, Bettua C, Orsi CF, et al. Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. Infection. 2016;44:223–33. Scholar
  3. 3.
    Wiederhold NP, Najvar LK, Vallor AC, et al. Assessment of Serum (1 → 3)-β-d-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2008;52:1176–8. Scholar
  4. 4.
    Ahmad S, Al-Shaikh AA, Khan Z. Development of a novel inhalational model of invasive pulmonary aspergillosis in rats and comparative evaluation of three biomarkers for its diagnosis. PLoS ONE. 2014;9:e100524. Scholar
  5. 5.
    Khodadadi H, Mirhendi H, Makimura K, et al. β-d-Glucan assay in diagnosis and monitoring the systemic candidiasis in a rat model. Jundishapur J Microbiol. 2014. Scholar
  6. 6.
    Linke MJ, Ashbaugh A, Collins MS, et al. Characterization of a distinct host response profile to pneumocystis murina asci during clearance of pneumocystis pneumonia. Infect Immun. 2013;81:984–95. Scholar
  7. 7.
    Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-d-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55:521–6. Scholar
  8. 8.
    Sims CR, Jaijakul S, Mohr J, et al. Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. J Clin Microbiol. 2012;50:2104–6. Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • P. Pini
    • 1
    • 2
  • C. Venturelli
    • 2
  • M. Girardis
    • 2
  • F. Forghieri
    • 2
  • E. Blasi
    • 1
    • 2
    Email author
  1. 1.Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Istituti BiologiciUniversità degli Studi di Modena e Reggio EmiliaModenaItaly
  2. 2.Azienda Ospedaliero Universitaria-PoliclinicoModenaItaly

Personalised recommendations